BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 23171385)

  • 1. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy.
    Fung J; Seto WK; Lai CL; Yuen J; Wong DK; Yuen MF
    J Hepatol; 2011 Feb; 54(2):195-200. PubMed ID: 21056499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
    J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Ito K; Arai M; Imazeki F; Yonemitsu Y; Bekku D; Kanda T; Fujiwara K; Fukai K; Sato K; Itoga S; Nomura F; Yokosuka O
    Scand J Gastroenterol; 2010; 45(2):243-9. PubMed ID: 20095888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B.
    Bekku D; Arai M; Imazeki F; Yonemitsu Y; Kanda T; Fujiwara K; Fukai K; Sato K; Itoga S; Nomura F; Yokosuka O
    J Gastroenterol Hepatol; 2011 Jan; 26(1):122-8. PubMed ID: 21175805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
    Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
    World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
    Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
    J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
    J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2012 Jan; 55(1):68-76. PubMed ID: 21858846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.